Tracers / [225Ac]Ac-90-NM600
[225Ac]Ac-90-NM600
Also written as Ac-225-NM600
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 2
What it is
- Compound class
- DOTA-conjugated alkylphosphocholine (tumor-targeting phospholipid ether analog)
- Target / mechanism
- Alkylphosphocholine analog that preferentially accumulates in most tumor types via tumor cell membrane lipid rafts, semiselectively delivering the radioisotope to the tumor microenvironment PMID 34261797
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | — | — | — | 42080948 2026 Neuro Oncol |
| Manual synthesis | — | SPE | >90% | — | NM600 | 41319721 2026 Int J Radiat Oncol Biol Phys We performed radiolabeling of NM600 with 177Lu or 225Ac as follows: (10 μg per mCi for 177Lu and 100 μg per mCi for 225Ac) in 0.1 M NaOAc buffer (pH 5.5) for 30 minute at 90 °C. — Radiolabeling yield was above 90% for both isotopes |
Need this precursor?We can point you to suppliers for [225Ac]Ac-90-NM600, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 34383787: 'NM600 (18-(4-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)phenyl)octadecyl) phosphate (NM600)'.